acute myeloid leukemia
Conditions
Interventions
trial group:CAGV regimen
Sponsors
The First Affiliated Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Age over 60 years old, or no more than 60 years old but assessed by the researcher as unsuitable for conventional chemotherapy. (2) Diagnosed as AML according to the WHO 2016 classification criteria for hematopoietic and lymphoid tissue tumors. (3) ECOG PS <= 2. (4) Having sufficient liver and kidney function, defined as follows: liver function: serum total bilirubin (TBIL) < 2 x upper limit of normal value (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are less than 3 × ULN. Renal function: Serum creatinine (Cr) < 2 x ULN. (5) Voluntary participation, willingness to provide the above treatment data, and signed informed consent.
Exclusion criteria
Exclusion criteria: (1) Patients who are allergic to the medication used in this study (2) Patients with unstable or active cardiovascular diseases, or with active infections that have not been effectively controlled by medication within one week prior to the first treatment, or with HBV and HCV active infections (3) Patients who have received anti-leukemia treatment before the study, excluding those who have previously been diagnosed with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) and received demethylation therapy (decitabine or azacitidine) (4) Diagnosed as acute promyelocytic leukemia, or patients with central nervous system symptoms who are suspected of central nervous system leukemia or other central diseases (5) Combined with other malignant tumors that still require treatment (6) Serious mental or neurological disorders that affect informed consent and/or expression or observation of adverse reactions (7) Pregnant, lactating women, and childbearing age patients who are unwilling to take contraceptive measures (8) Patients who cannot be followed up (9) The researcher determined that they are not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall response rate (ORR); | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of response (DOR);12-month survival rate;Adverse events (AEs) of the treatment protocol; | — |
Countries
China
Contacts
Public ContactJingsong He; Xiujin Ye
The First Affiliated Hospital, Zhejiang University School of Medicine
Outcome results
None listed